Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic infecting more than 106 million people and causing 2.3 million deaths …

Potent neutralizing monoclonal antibodies are one of the few agents currently available to
treat COVID-19. SARS-CoV-2 variants of concern (VOCs) that carry multiple mutations in the …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

The Covid-19 pandemic has ravaged the globe, and its causative agent, SARS-CoV-2,
continues to rage. Prospects of ending this pandemic rest on the development of effective …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Most known SARS-CoV-2 neutralizing antibodies (nAbs), including those approved by the
FDA for emergency use, inhibit viral infection by targeting the receptor-binding domain …

The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …

Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

The increasing prevalence of SARS-CoV-2 variants with mutations in the spike protein has
raised concerns that recovered individuals may not be protected from reinfection and that …